• European Commission grants approval for Gotenfia^®, a golimumab biosimilar to Simponi^® that was developed by Bio-Thera and will be marketed by STADA
• Launch preparations are underway to bring the second approved golimumab biosimilar to patients across Europe in the coming weeks and months
• Bio-Thera is responsible for development, manufacture and supply; STADA for commercialization in the EU, the UK, Switzerland and selected other countries

Global specialty, generic and consumer healthcare medicines company STADA and Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, have received a marketing authorization from the European Commission[1] for their Gotenfia^® (golimumab) biosimilar referencing Simponi^®.

The authorization of Gotenfia^® for several chronic inflammatory autoimmune diseases[2], which applies across the European Union (EU and European Economic Area (EEA), follows a recommendation in December 2025 from the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA). Launch preparations are underway to bring this therapeutic option to patients across Europe in the coming weeks and months. Being the second biosimilar to Simponi^® approved in the EU, Gotenfia^®  ̵  developed by Bio-Thera under the product code BAT2506  ̵  will significantly spur market competition, which is expected to increase treatment access for many more patients at lower unit costs.

"Having received the European marketing authorization, our 11^th for a biosimilar in total, we look forward to increasing competition on this well-established anti-TNF therapy," commented STADA's Global Specialty Head, Bryan Kim. "We know from our years of experience supplying adalimumab and ustekinumab biosimilars the considerable impact that access to biological treatments for chronic autoimmune and inflammatory conditions can have on patients' quality of life."

"Bringing this convenient, once-monthly treatment option to rheumatologists, gastroenterologists and the patients they serve marks a major milestone in Bio-Thera's commitment to being one of the premier biosimilar developers and manufacturers in the world," said Shengfeng Li, CEO of Bio-Thera Solutions. "Building on our prior approvals and launches in the US and EU, this European authorization further establishes Bio-Thera as a major global biosimilar developer and manufacturer."

The marketing authorization and positive CHMP opinion on Gotenfia^® were based on the totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package demonstrating that Gotenfia^® is biosimilar to its reference product. The marketing authorization for Gotenfia^® 50mg/0.5mL and 100mg/mL solution for injection in pre-filled syringes with passive needle safety guards applies across the 27 EU member states, in addition to Norway, Iceland and Lichtenstein.

 Bio-Thera and STADA entered into a license and commercialization agreement for BAT2506 in May 2024[3]. Under the terms of the agreement, Bio-Thera is responsible for development, manufacture and commercial supply. STADA holds exclusive rights to commercialize the product in the European Union (EU), the UK, Switzerland and selected other countries. In 2025, the two partners announced an extension of their alliance to cover the immunosuppressant monoclonal antibody tocilizumab[4] for which launch preparations are also underway.